Abstract
Ovarian cancer (epithelial ovarian cancer - EOC) is a gynecological malignancy with the worst prognosis. It is considered a chemosensitive disease.
Paclitaxel and carboplatin chemotherapy was (till 2011) more than 15 years the standard treatment regime. New hope for patients with ovarian cancer is chemotherapy combined with targeted antiangiogenic therapy with bevacizumab.
Bevacizumab is a humanized monoclonal antibody against key factor in angiogenesis, vascular endothelial growth factor (VEGF). There is its efficiency is proven and demonstrated in a number of cancers.
Described case of patient shows the contribution of addition of bevacizumab to chemotherapy in repeatedly relapsed ovarian cancer according to the results of clinical research.